Therefore, our data suggest that regulating AR activity indirectly through FKBP52 either by ID4‐ or by FKBP52‐specific inhibitors such as MJC13 would be a valuable pharmacological tool for selectively attenuating persistent AR activity in CRPC, irrespective of hormonal milieu of the cancer. Here, AR is linked to cancer.